Lipidic vehicles as chronotherapeutic drug delivery devices

Description:
Reference Number:1724

Background

The severity of many diseases such as anxiety, asthma and hypertension varies with the bodies’ internal clock. There is increasing evidence to show that these natural rhythms can also affect the bodies responsiveness to drugs and so optimal treatment of these diseases could be enhanced by delivery of the drug at the time when clinical signs develop or increase.

Technology

Researchers at the University of Strathclyde have developed a novel platform oral delivery system that provides optimal controlled drug release profiles without the need for expensive and time consuming processes. This technology provides a simple cost-effective platform that can be used to deliver combinations of drugs to the body at optimal times to maximise therapeutic benefit.

Key Benefits

  • Oral drug delivery platform technology with the unique ability to deliver drug combinations in complex release patterns
  • The delivery device performs independently of gastrointestinal pH to allow time-specific release
  • Streamlined manufacturing process that is readily scaleable
  • This delivery device presents the opportunity to aid patient compliance and has the potential to minimise drug related side effects

Markets and Applications

This is a platform technology and so the market potential of this delivery system is broad – clinical areas for application of this technology include, but are not limited to, hypertension, asthma, anxiety, epilepsy, pain, sleep disorders and infections.

Licensing and Development

The technology is a novel finding that constitutes a patentable invention. The IP is protected through non-disclosure and contact is welcomed from organisations interested in developing or exploiting this technology

For further information, please contact Research & Knowledge Exchange Services:
e: rkes@strath.ac.uk t: 0141 548 3707 f: 0141 552 4409

This project has received assistance from the Proof of Concept Fund managed by Scottish Enterprise. The Proof of Concept Fund supports the pre-commercialisation of leading-edge technologies emerging from Scotland's universities, research institutes and NHS Trusts.

Patent Information:
Category(s):
Drug Delivery
For Information Contact: rkes@strath.ac.uk
University of Strathclyde
Inventors:
Alexander Mullen
Howard Stevens
Sarah Eccleston
Keywords:
© 2026. All Rights Reserved. Powered by Inteum